Ritodrine
Clinical data
Pronunciation/ˈraɪtoʊdriːn/ RY-toh-dreen
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		Oral (tablets), parenteral (IV)
ATC code
Legal status
Legal status
  • US: Discontinued
Pharmacokinetic data
Protein binding~56%
MetabolismHepatic, metabolites are inactive[1]
Elimination half-life1.7–2.6 hours
Identifiers
  • 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.043.512
Chemical and physical data
FormulaC17H21NO3
Molar mass287.359 g·mol−1
3D model (JSmol)
  • O[C@H](c1ccc(O)cc1)[C@@H](NCCc2ccc(O)cc2)C
  • InChI=1S/C17H21NO3/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13/h2-9,12,17-21H,10-11H2,1H3/t12-,17-/m0/s1 checkY
  • Key:IOVGROKTTNBUGK-SJCJKPOMSA-N checkY
  (verify)

Ritodrine (trade name Yutopar) is a tocolytic drug used to stop premature labor.[2] This drug has been removed from the US market, according to FDA Orange Book. It was available in oral tablets or as an injection and was typically used as the hydrochloride salt, ritodrine hydrochloride.

Mechanism

Ritodrine is a short-acting β2 adrenoreceptor agonist — a class of medication used for smooth muscle relaxation (other similar drugs are used in asthma or other pulmonary diseases such as salbutamol (albuterol)). Since ritodrine has a bulky N-substituent, it has high β2 selectivity. Also, the 4-hydroxy group on the benzene ring is important for activity as it is needed to form hydrogen bonds. However, the 4-hydroxy group makes it susceptible to metabolism by catechol-O-methyl transferase (COMT). Since it is β2-selective it is used for premature labor.[3]

Side effects and potential contraindications

Most side effects of β2 agonists result from their concurrent β1 activity, and include increase in heart rate, rise in systolic pressure, decrease in diastolic pressure, chest pain secondary to myocardial infarction, and arrhythmia. Beta agonists may also cause fluid retention secondary to decrease in water clearance, which when added to the tachycardia and increased myocardial work, may result in heart failure. In addition, they increase gluconeogenesis in the liver and muscle resulting in hyperglycemia, which increases insulin requirements in diabetic patients. The passage of β agonists through the placenta does occur and may be responsible for fetal tachycardia, as well as hypoglycemia or hyperglycemia at birth.

Patients with type 2 diabetes, high blood pressure or migraines should bring this to their doctor's attention before receiving care.

It has also been associated with postpartum bleeding.

References

  1. ↑ Finkelstein, BW (1981). "Ritodrine (Yutopar, Merrell Dow Pharmaceuticals Inc.)". Drug Intelligence & Clinical Pharmacy. 15 (6): 425–33. doi:10.1177/106002808101500601. S2CID 75942075.
  2. ↑ Li X, Zhang Y, Shi Z (February 2005). "Ritodrine in the treatment of preterm labour: a meta-analysis" (PDF). The Indian Journal of Medical Research. 121 (2): 120–7. PMID 15756046. Archived from the original (PDF) on 2019-08-25. Retrieved 2008-10-05.
  3. ↑ Medicinal Chemistry of Adrenergics and Cholinergics Archived 2010-11-04 at the Wayback Machine
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.